741
Participants
Start Date
February 3, 2025
Primary Completion Date
April 30, 2029
Study Completion Date
April 30, 2029
Optune® device
Optune® device delivering TTFields therapy at 200 kHz.
Temozolomide
Temozolomide per approved labeling.
Pembrolizumab
Pembrolizumab dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
Placebo
Placebo (saline solution) dose throughout this study is 200 mg IV Q3W for a maximum of 35 cycles.
RECRUITING
University Hospital Basel Medical Oncology, Basel
RECRUITING
University Hospital Zurich, Zurich
RECRUITING
Columbia University Irving Medical Center, New York
RECRUITING
Montefiore Medical Center- Montefiore Medical Park, The Bronx
RECRUITING
Northwell Health, Lake Success
RECRUITING
Hopital de la Timone, Marseille
RECRUITING
UPMC Hillman Cancer Center, Pittsburgh
RECRUITING
Hospital Universitario Virgen de las Nieves, Granada
RECRUITING
Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Clinical Trials Organization, Philadelphia
RECRUITING
University of Maryland, Baltimore
RECRUITING
Inova Schar Cancer Institute, Fairfax
RECRUITING
Duke University Medical Center, Durham
RECRUITING
Hospital Universitario Ramón y Cajal, Madrid
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
Institut Claudius Regaud, Toulouse
RECRUITING
Mayo Clinic - Florida, Jacksonville
RECRUITING
UF Health Neuromedicine, Gainesville
RECRUITING
Miami Cancer Institute, Miami
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
University of Kentucky Medical Center, Lexington
RECRUITING
Hospital Universitario Virgen del Rocio, Seville
RECRUITING
University Hospitals Cleveland Medical Center, Cleveland
RECRUITING
The Cleveland Clinic, Cleveland
RECRUITING
Universitätsklinikum Essen, Essen
RECRUITING
Hospital Universitari i Politécnic La Fe, Valencia
RECRUITING
Masonic Cancer Center, University of Minnesota, Minneapolis
RECRUITING
Mayo Clinic - Rochester, Rochester
RECRUITING
Washington University, St Louis
RECRUITING
Tel-Aviv Sourasky Medical Center, Tel Aviv
RECRUITING
Centre Hospitalier Universitaire de Lyon, Bron
RECRUITING
Hopital Saint-Louis, Paris
RECRUITING
Groupe Hospitalier Pitie - Salpetriere, Paris
RECRUITING
The University of Texas, Houston
RECRUITING
University of Texas, MD Anderson Cancer Center, Houston
RECRUITING
Huntsman Cancer Institute, University of Utah, Salt Lake City
RECRUITING
Mayo Clinic Hospital, Phoenix
RECRUITING
University of Southern California, Los Angeles
RECRUITING
Hoag Memorial Hospital Presbyterian, Newport Beach
RECRUITING
Stanford Cancer Institute, Palo Alto
RECRUITING
Swedish Medical Center, Seattle
RECRUITING
Rabin Medical Center- Beilinson Hospital, Petah Tikva
RECRUITING
Chaim Sheba Medical Center, Ramat Gan
RECRUITING
Tufts Medical Center, Boston
RECRUITING
John Theurer Cancer Center/ Hackensack Meridian Health, Hackensack
RECRUITING
Rhode Island Hospital, Providence
RECRUITING
Nemocnice Na Homolce, Prague
RECRUITING
Kyushu University Hospital, Fukuoka
RECRUITING
Hokkaido University Hospital, Hokkaido
RECRUITING
Kanazawa University Hospital, Ishikawa
RECRUITING
Kumamoto University Hospital, Kumamoto
RECRUITING
Kyoto University Hospital, Kyoto
RECRUITING
Kyorin University Hospital, Mitaka
RECRUITING
Nagoya University Hospital, Nagoya
RECRUITING
Saitama Medical University International Medical Center, Saitama
RECRUITING
Tohoku University Hospital, Sendai
RECRUITING
National Cancer Center Hospital, Tokyo
RECRUITING
Hospital Universitari Vall d'Hebron, Barcelona
RECRUITING
Institut Català d'Oncologia de L'Hospitalet (ICO L'Hospitalet), Barcelona
RECRUITING
Addenbrooke's Hospital (Cambridge University Hospitals NHS Foundation Trust), Cambridge
RECRUITING
Western General Hospital, Edinburgh
RECRUITING
The Christie Hospital, Manchester
RECRUITING
Weston Park Hospital, Sheffield
RECRUITING
Southampton General Hospital, Southampton
RECRUITING
Royal Marsden, Sutton
Merck Sharp & Dohme LLC
INDUSTRY
NovoCure GmbH
INDUSTRY